SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of various crypto tokens attempting to capitalize on the highly anticipated, multi-trillion dollar SpaceX IPO. While some participants are seeking exposure through the tokenized assets, others are warning of a potential scam, urging caution against the speculative hype surrounding Elon Musk's companies.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

The 4CHAN token is trending as community members position it as the "source code" of internet meme culture, aggressively promoting its potential for explosive growth based on its scarcity and symbolic value. While some critics view it as a high-risk speculative play, proponents are actively buying dips and emphasizing its community-driven, renounced contract as a stable hedge against broader market volatility.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is experiencing significant volatility and downward pressure as investors navigate sector-wide weakness and frustration over the stock's inability to maintain gains despite steady contract wins. While the community is actively debating whether the stock has bottomed or needs more time to heal, many remain bullish on the long-term outlook, highlighting strong fundamental backlog and the company's role in government, nuclear, and space infrastructure as key reasons to maintain their positions.

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

4D Molecular Therapeutics Inc

4D Molecular Therapeutics is attracting significant attention as investors react to positive Phase 2 SPECTRA trial data for 4D-150 in diabetic macular edema, sparking discussions about its potential as a best-in-class, durable gene therapy. While the community is actively debating the company's valuation relative to its cash position and the timeline for upcoming pivotal data, momentum traders are closely monitoring price action and short interest as the company prepares for upcoming investor conferences.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as investors scrutinize the company's $125 million acquisition by Garda Therapeutics at $18 per share, which many long-term shareholders feel significantly undervalues the core Rolvedon asset and follows a series of questionable portfolio divestitures. The community remains highly vocal about potential fiduciary failures, expressing intense frustration over management's decision-making and demanding accountability while waiting for the Schedule 14D-9 to clarify the valuation process.

Space and Time is the data blockchain securing onchain finance. Backed by Microsoft’s Venture Fund M12, Space and Time connects real-world data to onchain systems to power tokenized assets, stablecoins, institutional markets, and DeFi.  The SXT token is deployed as an ERC-20 token on Ethereum and functions as the network's native utility token. SXT is used for staking, data processing payments, access control, and incentives for data contributors.

Space and Time

Space and Time (SXT) is generating significant community buzz driven by its core infrastructure play in verifiable data, notably bolstered by its backing from Microsoft and its recent mainnet launch. Investors are debating the project's long-term utility in the AI and DeFi sectors, often weighing the potential for institutional adoption against frustration over current price volatility and recent token unlocks.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is drawing significant attention as community members debate its potential against other meme coins like UpDog and Aircoin, with active discussions focusing on technical price levels and the coin's volatile, speculative nature. Traders remain divided, with some betting on a massive breakout based on historical patterns while others criticize it as a short-term gamble within an oversaturated meme market.

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

ANI Pharmaceuticals Inc

ANI Pharmaceuticals is experiencing positive momentum driven by strong demand for its rare disease franchise, particularly Cortrophin Gel, and a robust pipeline of new product launches. The community is actively discussing the company's improved financial guidance and strategic efforts to scale its rare disease portfolio, while some remain cautious about broader sector headwinds and historical share price performance.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is currently facing significant volatility as investors digest a mixed bag of news, including the latest FDA label expansion for its oncology drug Libtayo and ongoing regulatory scrutiny surrounding a third-party manufacturing facility. While analysts remain bullish on the long-term potential of its core Eylea franchise and pipeline, community sentiment is fractured between those viewing recent pullbacks as an attractive buying opportunity and others expressing frustration over the stock's sluggish price performance despite positive clinical milestones.

Schwab Strategic Trust - Schwab U.S. Large-Cap Growth ETF

Investors are actively debating the long-term compounding potential of SCHG as a core growth holding, often comparing it to dividend-focused alternatives like SCHD to build balanced portfolios. Sentiment is split between those who view current dips as strategic entry points for aggressive growth and others who are frustrated by recent performance lags compared to broader market indices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Astronics (ATRO) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Astronics Corporation (ATRO) Q1 Earnings and Revenues Top Estimates

Astronics (ATRO) delivered earnings and revenue surprises of +7.27% and +3.51%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Astronics Corporation Reports 12% Sales Growth for First Quarter 2026

Astronics Corporation (Nasdaq: ATRO) (Astronics or the Company), a leading supplier of advanced technologies and products to the global aerospace, defense, and other mission critical industries...

ATRO Outperforms Industry in a Month: Should You Buy the Stock?

ATRO gains on strong aerospace innovation, rising earnings estimates and discounted valuation, positioning the stock for long-term growth.

Should You Buy, Hold or Sell Astronics Stock Ahead of Q1 Earnings?

ATRO heads into Q1 earnings with strong aerospace demand, margin expansion and a 157.2% stock surge over the past year.

Astronics (ATRO) is on the Move, Here's Why the Trend Could be Sustainable 

If you are looking for stocks that are well positioned to maintain their recent uptrend, Astronics (ATRO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Kratos (KTOS) Beats Q1 Earnings and Revenue Estimates

Kratos (KTOS) delivered earnings and revenue surprises of +26.28% and +7.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Astronics (NASDAQ:ATRO) Stock Rating Upgraded by Truist Financial

Truist Financial upgraded Astronics to a "strong-buy" rating in a research note on Monday...

Is Astronics (ATRO) Outperforming Other Aerospace Stocks This Year?

Here is how Astronics Corporation (ATRO) and BWX Technologies (BWXT) have performed compared to their sector so far this year.

Astronics (OTCMKTS:ATROB) Shares Gap Down - Time to Sell?

Astronics (OTCMKTS:ATROB) Shares Gap Down - Here's Why...

Astronics Corp. engages in the provision of electrical power generation and distribution systems. It includes motion systems, lighting and safety systems, avionics products, aircraft structures, systems certification, and automated test systems. It operates through the Aerospace and Test Systems segments. The Aerospace segment designs and manufactures products for the global aerospace industry. The Test Systems segment designs, develops, manufactures and maintains communications and weapons test systems and training and simulation devices for military applications. The firm's products and solutions include Aircraft Data Systems, Aircraft Electrical Power Systems, Airfield Lighting, Custom Design & Manufacturing, Emergency Systems, Enhanced Vision Systems, IFC Antennas and Radome Systems, Inflight Entertainment System Hardware, Interiors & Structures, Lighting Systems, Seat Actuation Systems, Simulation & Training, Systems Certification, Test & Measurement and VIP IFEC & CMS Systems. The company was founded on December 5th, 1968 and is headquartered in East Aurora, NY.

Current Price	$78.59
Prev Close	$82.71
Open	$80.21
Dividend Yield	0.00%
50-Day Moving Average	$72.22
Beta	1.39
Avg. Volume	411,634.54
PE Ratio	67.18

52-Week High	$83.96
52-Week Low	$27.27
Market Capitalization	$2.81B
EPS (Annual)	$0.8052
Price to Book	17.42
Revenue Per Employee	$319,306.67

ATRO
Astronics Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATRO News

ATROAstronics Corp.